626 hasil
Menampilkan 1–20 · 0,13 detik · RSS
Cancer Immunology, Immunotherapy
Scopus
ISSN 1432-0851 · Springer · 626 artikel di indeks
-
Artikel Jurnal
Enhanced antitumor efficacy of combined targeting of adenosine A2B receptor and PD-1 is mediated via multiple effects on different cell populations within tumor microenvironment
Abstract Background Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of non-small cell lung cancer (NSCLC). However, their low response rates and poor 5-year survivals indicate a need for improvement. One key factor in this resistance may be molecules that mediate…
-
Artikel Jurnal
Pattern of disease recurrence and outcomes after progression of high-risk renal cell carcinoma (RCC) patients treated with adjuvant immunotherapy
Abstract Background Radical or partial nephrectomy followed by adjuvant pembrolizumab is the standard of care for high-risk localized renal cell carcinoma (RCC), yet around 40% of patients relapse within 5 years. We investigated patterns of disease recurrence and the clinical management of RCC…
-
Artikel Jurnal
A real-world comparison of nivolumab plus cabozantinib and pembrolizumab plus lenvatinib focusing on safety outcomes in metastatic renal cell carcinoma: results from the JK-FOOT consortium
Abstract Purpose Immune checkpoint inhibitor (ICI)-based combination therapy is a standard first-line treatment for metastatic renal cell carcinoma (mRCC), with combinations such as nivolumab plus cabozantinib (Nivo + Cabo) and pembrolizumab plus lenvatinib (Pem + Len) demonstrating favorable…
-
Artikel Jurnal
PD-1 inhibitors combined with induction chemotherapy followed by chemoradiotherapy in HPV-negative locally advanced head and neck squamous cell carcinoma: a real-world study
Abstract Purpose To compare the efficacy of induction chemotherapy with or without PD-1 inhibitors followed by chemoradiotherapy (CCRT) among patients with human papillomavirus (HPV)-negative locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Materials and methods We retrospectively…
-
Artikel Jurnal
Defining alteration in bone marrow mesenchymal stem cells (MSC) from acute myeloid leukemia and exploring cultured MSC-conditioned media as a novel anti-leukemia therapy agent
Abstract Background Bone marrow-resident mesenchymal stem cells (BM-MSC) often play a role in acute myeloid leukemia (AML) progression and drug resistance by exerting immunomodulatory effects on cellular as well as soluble milieu. The current study aimed to understand the dynamic interplay between…
-
Artikel Jurnal
Tumor-specific antibody cocktail treatment suppresses colorectal tumor growth in mice
Abstract Background Colorectal cancer (CRC) remains a leading cause of cancer-related mortality, with advanced-stage disease frequently marked by treatment resistance and recurrence. Tumor heterogeneity, driven by the accumulation of somatic mutations, undermines the efficacy of conventional…
-
Artikel Jurnal
Integrative analysis of T cell subset-specific ICOS expression and tumor HLA class I/II expression in lung adenocarcinoma: implications for their interaction and clinical outcome
Abstract Objectives Inducible T cell costimulator (ICOS) is a CD28-family costimulatory receptor with bidirectional therapeutic effects on antitumor immunity, and HLA-mediated tumor recognition is essential for effective T cell responses. However, their clinicopathological significance in lung…
-
Artikel Jurnal
Heterologous prime-boost immunization of AAV-based neoantigen cancer vaccine induces anti-tumor immunity to inhibit tumor growth and relapse
Abstract Therapeutic cancer vaccines, which induce anti-tumor immunity by targeting specific antigens, constitute a promising approach to cancer therapy. Our previous work developed a novel engineered adenovirus-associated virus 2 (AAV2)-based tumor-specific (neoantigen) cancer vaccine to boost…
-
Artikel Jurnal
CAR T cells derived from a novel, high-affinity anti-CLL-1 monoclonal antibody exhibit a significant anti-AML effect
Abstract CAR T cells targeting CLL-1 have shown antileukemia efficacy in patients with acute myeloid leukemia (AML). However, CLL-1low/− AML cells are present in some patients, suggesting that the development of CAR T cells with high sensitivity is necessary to eradicate all AML clones in these…
-
Artikel Jurnal
Dasatinib boosts γδ T cell expansion and memory phenotypes with enhanced antitumor immunity
Abstract Γδ T cells offer unique advantages in cancer immunotherapy because of their MHC-independent recognition of tumor antigens and innate cytotoxic potential. However, conventional ex vivo expansion protocols using zoledronic acid (Zol) and IL-2 often lead to terminal differentiation and…
-
Artikel Jurnal
Nintedanib enhances the antitumor efficacy of pd-1 blockade, potentially through inhibition of myeloid-derived suppressor cells and cancer-associated fibroblasts
Abstract Although programmed cell death-1 (PD-1) inhibitors have shown promising and durable responses in patients with several types of cancer, many patients show resistance to PD-1 inhibitors. Recent evidence has demonstrated that immunosuppressive cells are induced in tumor microenvironment and…
-
Artikel Jurnal
Clinical and immunological implications of lymphocyte-activation gene 3 expression in metastatic colorectal cancer
Abstract Background Lymphocyte-activation gene 3 (LAG3), an inhibitory immune checkpoint receptor, has emerged as a potential therapeutic target in various cancer, including colorectal cancer (CRC). However, its prognostic role and immunologic context in metastatic CRC (mCRC) remain unclear. This…
-
Artikel Jurnal
A STING-activating biomimetic mineralized nanovaccine triggers robust anti-tumor immunity
Abstract Tumor nanovaccines have attracted great interest recently, due to a variety of advantages including high stability, efficient antigen packing and delivery, and the capacity to elicit sustained anti-tumor immune responses. Despite these advantages, existing nanovaccines are constrained by…
-
Artikel Jurnal
Digital spatial profiling reveals additive effects of triple therapy on tumor microenvironment: anti-PD-L1, anti-VEGF, and PARP inhibition in mouse models
Abstract Background Immune checkpoint inhibitors show limited efficacy against immune-desert tumors, including ovarian cancer. We investigated triple therapy combining anti-programmed cell death-ligand 1 (PD-L1) antibody, anti-vascular endothelial growth factor (VEGF) antibody, and Poly ADP-ribose…
-
Artikel Jurnal
High PD-1 expression in pre-treatment peripheral lymphocytes associated with poor immune checkpoint inhibitor response in patients with recurrent or metastatic head and neck squamous cell carcinoma
Abstract Programmed cell death protein-1 (PD-1)/programmed cell death ligand 1 (PD-L1) blockade is the standard therapy for recurrent or metastatic head and neck squamous cell carcinoma (RMHNSCC), yet many patients exhibit poor responses. Potential non-invasive biomarkers for predicting treatment…
-
Artikel Jurnal
CAR-T cells co-expressing IL-7 and CCL19 promote epitope spreading to enhance antitumor immunity
Abstract Antigen heterogeneity remains a major obstacle to the effective application of chimeric antigen receptor (CAR)-T cell therapy in solid tumors. We investigated the potential of epitope spreading as a strategy to overcome this limitation and examined whether CAR-T cells concomitantly…
-
Artikel Jurnal
Radiotherapy enhances M1 macrophage immunogenic activity through IFNs induction and stimulation in TP53-wild type tumors
Abstract Radiotherapy (RT), widely employed in clinical practice to suppress tumor progression, exhibits an abscopal effect that enhances immunogenic activity to potentially benefit immunotherapeutic efficacy. However, the tumor types most likely to exhibit such effects remain unclear. Since…
-
Artikel Jurnal
Comparative efficacy of combination regimens based on interventional therapy and immune checkpoint inhibitors (ICIs) in patients with intermediate- and advanced-stage hepatocellular carcinoma: a systematic review, meta-analysis, and network meta-analysis
Abstract Background Combining interventional therapy with immune checkpoint inhibitors (ICIs) has shown potential benefits in hepatocellular carcinoma (HCC). However, comprehensive evidence on its efficacy and safety remains limited. Methods A systematic search of PubMed, Embase, Cochrane Library…
-
Artikel Jurnal
Effectiveness of ICI-ICI versus ICI-TKI combinations in patients with IMDC intermediate- and poor-risk metastatic renal cell carcinoma: a sub-analysis of the MEET-URO 33 study
Abstract Background Immune checkpoint inhibitor doublet (ICI-ICI) and ICI plus tyrosine kinase inhibitor (ICI-TKI) regimens are the cornerstone of treatment for metastatic renal cell carcinoma (mRCC), although no head-to-head comparisons are currently available. This study aimed to compare the…
-
Artikel Jurnal
First-line ipilimumab plus nivolumab in advanced merkel cell carcinoma: a meta-analysis of prospective trials and real-world validation cohort
Abstract Background Advanced Merkel cell carcinoma (MCC) has a high response rate to immune checkpoint blockade (ICB). While early phase studies have demonstrated activity of dual ICB with anti-PD-1 plus anti-CTLA-4 agents in both the first- and second-line settings, the role of combination therapy…